CovidResearchTrials by Shray Alag


CovidResearchTrials Covid 19 Research using Clinical Trials (Home Page)


Report for D006470: Hemorrhage NIH

(Synonyms: Hemorr, Hemorrh, Hemorrhage)

Developed by Shray Alag
Clinical Trial MeSH HPO Drug Gene SNP Protein Mutation


Correlated Drug Terms (2)


Name (Synonyms) Correlation
drug2486 The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care: Wiki 0.71
drug315 Baricitinib Wiki 0.27

Correlated MeSH Terms (19)


Name (Synonyms) Correlation
D001997 Bronchopulmonary Dysplasia NIH 0.71
D008595 Menorrhagia NIH 0.71
D006929 Hyperaldosteronism NIH 0.71
D014552 Urinary Tract Infections NIH 0.71
D054559 Hyperphosphatemia NIH 0.71
D004314 Down Syndrome NIH 0.71
D000309 Adrenal Insufficiency NIH 0.71
D007008 Hypokalemia NIH 0.71
D009080 Mucocutaneous Lymph Node Syndrome NIH 0.50
D001289 Attention Deficit Disorder with Hyperactivity NIH 0.35
D020141 Hemostatic Disorders NIH 0.21
D001778 Blood Coagulation Disorders NIH 0.21
D006973 Hypertension NIH 0.20
D004194 Disease NIH 0.13
D013577 Syndrome NIH 0.08
D003141 Communicable Diseases NIH 0.06
D007239 Infection NIH 0.04
D045169 Severe Acute Respiratory Syndrome NIH 0.04
D018352 Coronavirus Infections NIH 0.03

Correlated HPO Terms (8)


Name (Synonyms) Correlation
HP:0002905 Hyperphosphatemia HPO 0.71
HP:0002900 Hypokalemia HPO 0.71
HP:0000846 Adrenal insufficiency HPO 0.71
HP:0000132 Menorrhagia HPO 0.71
HP:0000859 Hyperaldosteronism HPO 0.71
HP:0007018 Attention deficit hyperactivity disorder HPO 0.35
HP:0001928 Abnormality of coagulation HPO 0.21
HP:0000822 Hypertension HPO 0.20

There are 2 clinical trials

Clinical Trials


1 Pharmacokinetics, Pharmacodynamics, and Safety Profile of Understudied Drugs

The study investigators are interested in learning more about how drugs, that are given to children by their health care provider, act in the bodies of children and young adults in hopes to find the most safe and effective dose for children. The primary objective of this study is to evaluate the PK of understudied drugs currently being administered to children per SOC as prescribed by their treating provider.

NCT04278404 Coronavirus Infection (COVID-19) Pulmonary Arterial Hypertension Urinary Tract Infections in Children Hypertension Pain Hyperphosphatemia Primary Hyperaldosteronism Edema Hypokalemia Heart Failure Hemophilia Menorrhagia In Insomnia Pneumonia Skin Infection Arrythmia Asthma in Children Bronchopulmonary Dysplasia Adrenal Insufficiency Fibrinolysis; Hemorrhage Attention Deficit Hyperactivity Disorder Multisystem Inflammatory Syndrome in Children (MIS-C) Kawasaki Disease Coagulation Disorder Down Syndrome Drug: The POP02 study is collecting bodily fluid samples (i.e., whole blood, effluent samples) of children prescribed the following drugs of interest per standard of care:
MeSH:Infection Communicable Diseases Urinary Tract Infections Coronavirus Infections Severe Acute Respiratory Syndrome Bronchopulmonary Dysplasia Down Syndrome Menorrhagia Hypertension Hemostatic Disorders Mucocutaneous Lymph Node Syndrome Blood Coagulation Disorders Hyperphosphatemia Hypokalemia Adrenal Insufficiency Hyperaldosteronism Disease Syndrome Hemorrhage Attention Deficit Disorder with Hyperactivity
HPO:Abnormality of coagulation Abnormality of the coagulation cascade Adrenal insufficiency Attention deficit hyperactivity disorder Hyperaldosteronism Hyperphosphatemia Hypertension Hypokalemia Menorrhagia Primary hyperaldosteronism

Primary Outcomes

Measure: Clearance (CL) or apparent oral clearance (CL/F) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Volume of distribution (V) or apparent oral volume of distribution (V/F) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Elimination rate constant (ke) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Half-life (t1/2) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Absorption rate constant (ka) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: AUC (area under the curve) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Maximum concentration (Cmax) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

Measure: Time to achieve maximum concentration (Tmax) as measured by PK sampling

Time: Data will be collected up to 90 days from the time of consent. For participants with Down Syndrome enrolling at sites designated as Down Syndrome sites, participants will be in the study for up to 210 days.

2 Prevalence of Severe Bleeding in COVID-19 Patients Treated With Higher Than Recommended Thromboprophylaxis Doses (BLEEDING Study)

The main objectives are: - To establish the prevalence of major bleeding in patients treated with higher than recommended thromboprophylaxis doses. - To identify variables associated to higher risk of bleeding.

NCT04380779 COVID-19
MeSH:Hemorrhage

Primary Outcomes

Description: Study endpoints are clinically recognized (and objectively confirmed) major and minor bleeding complications, and death.

Measure: Bleeding events and complications

Time: 30 days


HPO Nodes